Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo Suffers As It Waves Goodbye To Rx

CEO Kessler Acknowledges ‘Disappointing’ Q3 As Prescription Business Divested

Executive Summary

Perrigo CEO Murray Kessler has acknowledged “disappointing” third quarter results for the company during a transitional quarter that saw it finally divest its Rx prescription generics business ahead of its upcoming acquisition of consumer healthcare specialist HRA Pharma.

You may also be interested in...



Padagis Launches First-To-Market Zomig Nasal Spray Ahead Of Lannett

Less than six months into life as an independent company, former Perrigo Rx unit Padagis has realized its second generic launch, with the first-to-market entry of generic Zomig (zolmitriptan) nasal spray.

Perrigo Feels Chill From Q3 Results Due To ‘Unfulfilled’ Demand On Supply Chain Disruptions

“Unfulfilled orders' from retailers and other product distributors due to supply chain disruptions slowed revenues, net income and earnings per share during the quarter and prompted lower full-year guidance while also leaving analysts with doubts.

Perrigo Removes Irish Tax Overhang

Perrigo says it has removed a “major uncertainty” for its business after agreeing to pay €297m to settle an Irish tax assessment.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151428

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel